This site is intended for population health and access decision-makers in US health plans

Please verify that you are a US healthcare payer

The information on this page is intended for population health and access decision-makers in US health plans.

A comprehensive portfolio with innovative therapeutics

For more than 170 years, we've been at the forefront of innovative eye care products that may help people see better and live better. Our commitment to innovation is evident not only in our extensive portfolio but also in our dynamic pipeline:

checked
$324M invested in R&D in FY231
checked
60+ active projects in pipeline across all key R&D categories1

As we introduce or expand these innovations into the market through 2026, we aim to empower people everywhere to achieve clearer vision and a better quality of life.

We are an innovative eye health company,

empowering and educating patients across a broad spectrum of their eye health needs and their lives

Targeting significant eye care challenges

86 %

Studies have shown ~86% of patients with dry eye disease (DED) have excessive tear evaporation associated with meibomian gland dysfunction (MGD)2-4

Learn More
65 %

Clinically significant inflammation is present in up to 65% of DED cases5

Learn More
23 %

Patients with macular edema (ME) associated with uveitis incur 23% higher costs compared with those without ME6

Learn More
3 million people

Glaucoma affects ~3 million people in the US, and prevalence is increasing7

Learn More

Join our insiders’ network, Eyes on Innovation, for exclusive updates. Connect with a B+L account director.

Get updates + Connect with US

References:

1. Bausch + Lomb. 4Q23 & FY23 Financial results. Accessed June 17, 2024. https://ir.bausch.com/sites/bauschhealth-ir/files/2024-02/4q23-bausch-lomb-earnings-presentation.pdf 2. Lemp MA, Crews LA, Bron AJ, Foulks GN, Sullivan BD. Distribution of aqueous-deficient and evaporative dry eye in a clinic-based patient cohort: a retrospective study. Cornea. 2012;31(5):472-478. doi:10.1097/ICO.Ob013e318225415a 3. Badian RA, Utheim TP, Chen X, et al. Meibomian gland dysfunction is highly prevalent among first-time visitors at a Norwegian dry eye specialist clinic. Sci Rep. 2021;11(23412):1-8. doi:10.1038/s41598-021-02738-6 4. Rabensteiner OF, Aminfar H, Boldin I, et al. The prevalence of meibomian gland dysfunction, tear film and ocular surface parameters in an Austrian dry eye clinic population. Acta Ophthalmol. 2018;96:e707-e711. doi:10.1111/aos.13732 5. Sambursky R. Presence or absence of ocular surface inflammation directs clinical and therapeutic management of dry eye. Clin Ophthalmol. 2016;10:2337-2343. 6. Hariprasad SM, Joseph G, Gagnon-Sanschagrin P, et al. Healthcare costs among patients with macular oedema associated with non-infectious uveitis: A US commercial payer's perspective. BMJ Open Ophthalmol. 2021;6(1):e000896. Published online November 10, 2021. doi:10.1136/bmjophth-2021-000896 7. National Eye Institute. Glaucoma tables. Accessed June 17, 2024. https://www.nei.nih.gov/learn-about-eye-health/eye-health-data-and-statistics/glaucoma-data-and-statistics/glaucoma-tables